Pradaxa
[CAS# 872728-81-9]

Identification

• Classification: API >> Blood system medication >> Anticoagulant and antiplatelet drugs
• Name: Pradaxa
• Synonyms: Dabigatran etexilate mesylate; N-[[2-[[[4-[[[(Hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-beta-alanine ethyl ester monomethanesulfonat
• Molecular Formula: C₃₄H₄₁N₇O₅.CH₄O₃S
• Molecular Weight: 723.84
• CAS Registry Number: 872728-81-9 (593282-20-3)
• EC Number: 828-727-6
• SMILES: CCCCCCOC(=O)/N=C(/C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)N.CS(=O)(=O)O

Safety Data

• Hazard Symbols: GHS08 Danger
• Risk Statements: H361-H362-H372-H373-H413
• Safety Statements: P203-P260-P263-P264-P270-P273-P280-P318-P319-P405-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Specific target organ toxicity - repeated exposure	STOT RE	1	H372
Chronic hazardous to the aquatic environment	Aquatic Chronic	4	H413
Reproductive toxicity	Repr.	2	H361

Discovery and Applications

Pradaxa, known by its generic name dabigatran etexilate, is an oral anticoagulant used to prevent and treat various thromboembolic conditions. Dabigatran itself is a direct thrombin inhibitor that works by specifically inhibiting thrombin, an enzyme critical for blood clot formation. Pradaxa is the prodrug form of dabigatran, which is rapidly converted to the active compound in the body after oral administration.

The discovery of dabigatran dates back to the early 1990s when researchers sought to develop novel anticoagulants with a more predictable pharmacological profile than traditional warfarin. Warfarin, while effective, requires constant monitoring and has numerous food and drug interactions. The need for an alternative that would offer predictable anticoagulation effects without the need for frequent testing led to the development of dabigatran. It was first approved for medical use by the U.S. Food and Drug Administration (FDA) in 2010 under the brand name Pradaxa.

The primary application of Pradaxa is in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, a condition in which abnormal heart rhythms increase the risk of blood clots. It is also used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE), both of which are conditions where blood clots form in the veins and can travel to the lungs, potentially leading to fatal outcomes. Pradaxa has gained popularity due to its convenience as it does not require routine blood testing or dietary restrictions, unlike warfarin. It has shown similar or superior efficacy in preventing strokes and embolisms in patients with atrial fibrillation compared to other anticoagulants.

In addition to its use in treating thromboembolic disorders, Pradaxa is also used in the context of surgical procedures to prevent blood clots. For example, it is sometimes prescribed to patients undergoing hip or knee replacement surgery to reduce the risk of DVT or PE, which are common complications following such procedures.

Pradaxa has several advantages over traditional anticoagulants. Its fixed dosing regimen simplifies treatment, and it has a predictable anticoagulant effect, reducing the need for frequent monitoring. Additionally, it has a relatively short half-life, which allows for quick reversal in case of an emergency, such as bleeding complications. However, the use of Pradaxa is not without risks. The most significant concern is bleeding, as with all anticoagulants, and patients on Pradaxa are at an increased risk of gastrointestinal bleeding. The drug's use must be carefully monitored, particularly in individuals with renal impairment, as dabigatran is excreted primarily by the kidneys.

To address the risk of bleeding, the development of idarucizumab, a reversal agent for dabigatran, has provided an added layer of safety for patients using Pradaxa. Idarucizumab was approved in 2015 and is used in emergency situations to reverse the anticoagulant effects of dabigatran in cases of major bleeding or when immediate surgery is required.

In conclusion, Pradaxa is an important therapeutic agent in the management of thromboembolic disorders, offering a modern alternative to traditional anticoagulants. Its development has provided patients with a safer, more convenient option for the prevention and treatment of strokes, deep vein thrombosis, and pulmonary embolism. As with any anticoagulant, careful patient selection and monitoring are essential to minimize risks associated with bleeding.

References

2014. Safety of Electroconvulsive Therapy in Patients Receiving Dabigatran Therapy. Psychosomatics, 55(4).
DOI: 10.1016/j.psym.2013.06.010

2013. Higher Persistence in Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran Versus Warfarin. Circulation: Cardiovascular Quality and Outcomes, 6(5).
DOI: 10.1161/circoutcomes.113.000192

2010. Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement. The Journal of Clinical Pharmacology, 45(5).
DOI: 10.1177/0091270005274550